Points regarding cell transplantation for the treatment of spinal cord injury

Transplantation of somatic cells, including bone marrow stromal cells (BMSCs), bone marrow mononuclear cells (BMNCs), and choroid plexus epithelial cells (CPECs), enhances the outgrowth of regenerating axons and promotes locomotor improvements. They are not integrated into the host spinal cord, but...

Full description

Bibliographic Details
Main Authors: Chizuka Ide, Kenji Kanekiyo
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Neural Regeneration Research
Subjects:
Online Access:http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=7;spage=1046;epage=1049;aulast=Ide
_version_ 1818408001080393728
author Chizuka Ide
Kenji Kanekiyo
author_facet Chizuka Ide
Kenji Kanekiyo
author_sort Chizuka Ide
collection DOAJ
description Transplantation of somatic cells, including bone marrow stromal cells (BMSCs), bone marrow mononuclear cells (BMNCs), and choroid plexus epithelial cells (CPECs), enhances the outgrowth of regenerating axons and promotes locomotor improvements. They are not integrated into the host spinal cord, but disappear within 2-3 weeks after transplantation. Regenerating axons extend at the spinal cord lesion through the astrocyte-devoid area that is filled with connective tissue matrices. Regenerating axons have characteristics of peripheral nerves: they are associated with Schwann cells, and embedded in connective tissue matrices. It has been suggested that neurotrophic factors secreted from BMSCs and CPECs promote “intrinsic” ability of the spinal cord to regenerate. Transplanted Schwann cells survive long-term, and are integrated into the host spinal cord, serving as an effective scaffold for the outgrowth of regenerating axons in the spinal cord. The disadvantage that axons are blocked to extend through the glial scar at the border of the lesion is overcome. Schwann cells have been approved for clinical applications. Neural stem/progenitor cells (NSPCs) survive long-term, proliferate, and differentiate into glial cells and/or neurons after transplantation. No method is available at present to manipulate and control the behaviors of NPSCs to allow them to appropriately integrate into the host spinal cord. NPSP transplantation is not necessarily effective for locomotor improvement.
first_indexed 2024-12-14T09:36:47Z
format Article
id doaj.art-ab5ab41177d74915a11088aea933caa1
institution Directory Open Access Journal
issn 1673-5374
language English
last_indexed 2024-12-14T09:36:47Z
publishDate 2016-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Neural Regeneration Research
spelling doaj.art-ab5ab41177d74915a11088aea933caa12022-12-21T23:07:54ZengWolters Kluwer Medknow PublicationsNeural Regeneration Research1673-53742016-01-011171046104910.4103/1673-5374.187021Points regarding cell transplantation for the treatment of spinal cord injuryChizuka IdeKenji KanekiyoTransplantation of somatic cells, including bone marrow stromal cells (BMSCs), bone marrow mononuclear cells (BMNCs), and choroid plexus epithelial cells (CPECs), enhances the outgrowth of regenerating axons and promotes locomotor improvements. They are not integrated into the host spinal cord, but disappear within 2-3 weeks after transplantation. Regenerating axons extend at the spinal cord lesion through the astrocyte-devoid area that is filled with connective tissue matrices. Regenerating axons have characteristics of peripheral nerves: they are associated with Schwann cells, and embedded in connective tissue matrices. It has been suggested that neurotrophic factors secreted from BMSCs and CPECs promote “intrinsic” ability of the spinal cord to regenerate. Transplanted Schwann cells survive long-term, and are integrated into the host spinal cord, serving as an effective scaffold for the outgrowth of regenerating axons in the spinal cord. The disadvantage that axons are blocked to extend through the glial scar at the border of the lesion is overcome. Schwann cells have been approved for clinical applications. Neural stem/progenitor cells (NSPCs) survive long-term, proliferate, and differentiate into glial cells and/or neurons after transplantation. No method is available at present to manipulate and control the behaviors of NPSCs to allow them to appropriately integrate into the host spinal cord. NPSP transplantation is not necessarily effective for locomotor improvement.http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=7;spage=1046;epage=1049;aulast=Idenervbone marrow stromal cell; choroid plexus epithelial cell; Schwann cell; neural stem/progenitor cell; axonal regeneration; locomotor improvement; clinical application; intrinsic regeneration ability
spellingShingle Chizuka Ide
Kenji Kanekiyo
Points regarding cell transplantation for the treatment of spinal cord injury
Neural Regeneration Research
nervbone marrow stromal cell; choroid plexus epithelial cell; Schwann cell; neural stem/progenitor cell; axonal regeneration; locomotor improvement; clinical application; intrinsic regeneration ability
title Points regarding cell transplantation for the treatment of spinal cord injury
title_full Points regarding cell transplantation for the treatment of spinal cord injury
title_fullStr Points regarding cell transplantation for the treatment of spinal cord injury
title_full_unstemmed Points regarding cell transplantation for the treatment of spinal cord injury
title_short Points regarding cell transplantation for the treatment of spinal cord injury
title_sort points regarding cell transplantation for the treatment of spinal cord injury
topic nervbone marrow stromal cell; choroid plexus epithelial cell; Schwann cell; neural stem/progenitor cell; axonal regeneration; locomotor improvement; clinical application; intrinsic regeneration ability
url http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=7;spage=1046;epage=1049;aulast=Ide
work_keys_str_mv AT chizukaide pointsregardingcelltransplantationforthetreatmentofspinalcordinjury
AT kenjikanekiyo pointsregardingcelltransplantationforthetreatmentofspinalcordinjury